NVO
Novo Nordisk A/S (NVO) Stock Analysis
Research Novo Nordisk A/S (NVO) with company financials, earnings context, valuation indicators, risk analysis and related market news.
Research record updated: . Individual measures may refer to different reporting periods.
- Ticker
- NVO
- Company
- Novo Nordisk A/S
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Market cap
- $166.41B
- Financial data source
- FMP financial statements + FMP cash flow statements + FMP balance sheet + income statements + StockAnalysis complete statements
- Annual revenue (reporting year not supplied)
- $47.03B
- Annual net income (reporting year not supplied)
- $15.59B
- Annual free cash flow (reporting year not supplied)
- $4.41B
- Trailing revenue
- $50.13B
- Trailing net income
- $17.72B
- Total assets
- $82.61B
- Total liabilities
- $53.08B
Novo Nordisk A/S (NVO) Stock Analysis research
Novo Nordisk A/S develops and sells diabetes, obesity, and hormone therapies, led by Ozempic, Wegovy, Rybelsus, and insulin products. Its core advantage is deep expertise in GLP-1 medicines, which reduce blood sugar and appetite, creating a powerful position in rapidly expanding metabolic-care markets. Recent Seeking Alpha coverage and comparable financial commentary have focused on slowing prescription momentum, stronger Eli Lilly competition, pricing pressure, supply normalization, and the need for successful pipeline launches. Key technologies include oral GLP-1 treatments that could make obesity therapy easier to use, CagriSema, which combines semaglutide with another appetite-regulating mechanism, and amycretin, a next-generation hormone therapy designed to improve weight loss and metabolic control. These programs could be game changers if they deliver stronger results, simpler dosing, or better tolerability than current injections. The central investment question is whether Novo can convert its scientific leadership into renewed growth while protecting margins and market share. Within Healthcare, Novo remains a large, profitable, globally influential company with stronger structural growth than much of the broader market, although sentiment is less enthusiastic because competition and execution concerns have increased. I rate it 8/10 in its sector; its valuation appears attractive relative to its earnings power, while its quality, cash generation, and obesity-market exposure support a strong sector-based value assessment. The performance record suggests recovering momentum, but high volatility and a weak risk-adjusted return indicate that investors are still uncertain. In simple terms, the business is financially powerful and generates substantial cash, yet meaningful debt, premium book valuation, pricing pressure, and possible pipeline disappointment could limit future upside. Bullish.
Review the available company profile, financial history, valuation context and investor signals for Novo Nordisk A/S. Compare the reported operating results with the valuation and risk measures below.
The figures are cached research data and can change after new filings, earnings reports or market updates. Verify material facts with primary company disclosures before making an investment decision.